A controlled clinical trial to evaluate the effect of GanedenBC30 on immunological markers

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 32, Issue 2, 2010, Pages 129-132

  Kimmel, M ^a   Keller, D ^b   Farmer, S ^b   Warrino, D E ^c  

^a Accelovance Inc   (United States)

^b Ganeden Biotech Inc   (United States)

^c IBT Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; GAMMA INTERFERON; GANEDENBC 30; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PROBIOTIC AGENT; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; CD3+ T LYMPHOCYTE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; EX VIVO STUDY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL PARAMETERS; MALE; OPEN STUDY; VIRAL RESPIRATORY TRACT INFECTION; VIRUS STRAIN; ADENOVIRUS; ADOLESCENT; CLINICAL TRIAL; HUMAN ADENOVIRUS INFECTION; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H3N2; METABOLISM; RESPIRATORY TRACT INFECTION; VIROLOGY;

ADENOVIRIDAE; ADENOVIRUS INFECTIONS, HUMAN; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; FEMALE; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; INTERFERON-GAMMA; INTERLEUKIN-8; MALE; PROBIOTICS; RESPIRATORY TRACT INFECTIONS; YOUNG ADULT;

EID: 77954913123     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2010.32.2.1423881     Document Type: Article

References (23)

1. O'Hara, A.M., Shanahan, F. The gut flora as a forgotten organ. EMBO Rep 2006, 7(7): 688-93.
2. Dominguez-Bello, M.G., Blaser, M.J. Do you have a probiotic in your future? Microbes Infect 2008, 10(9): 1072-6.
3. Sanders, M.E. Probiotics: Definition, sources, selection and uses. Clin Infect Dis 2008, 46(Suppl. 2): S58-S61.
4. Cross, M.L., Ganner, A., Teilab, D., Fray, L.M. Patterns of cytokine induction by gram-positive and gram-negative probiotic bacteria. FEMS Immunol Med Microbiol 2004, 42(2): 173-80.
5. Chin, J., Turner, B., Barchia, I., Mullbacher, A. Immune response to orally consumed antigens and probiotic bacteria. Immunol Cell Biol 2000, 78(1): 55-66.
6. Matsuzaki, T., Chin, J. Modulating immune responses with probiotic bacteria. Immunol Cell Biol 2000, 78(1): 67-73.
7. Yasui, H., Kiyoshima, J., Hori, T. Reduction of influenza virus titer and protection against influenza virus infection in infant mice fed Lactobacillus casei Shirota. Clin Diagn Lab Immunol 2004, 11(4): 675-9.
8. Yasui, H., Shida, K., Matsuzaki, T., Yokokura, T. Immunomodulatory function of lactic acid bacteria. Antonie Van Leeuwenhoek 1999, 76(1-4): 383-9.
9. Baron, M. A patented strain of Bacillus coagulans increased immune response to viral challenge. Postgrad Med 2009, 121(2): 114-8.
10. Kalman, D., Schwartz, H., Alvarez, P., Feldman, S., Pezzullo, J., Krieger, D. A prospective, randomized, double-blind, placebo-controlled parallelgroup dual site trial to evaluate the effects of Bacillus coagulans-based product on functional intestinal gas symptoms. BMC Gastroenterology 2009, 9: 85.
11. Maathuis, A., Keller, D., Farmer, S. Survival and metabolic activity of the GanedenBC30 strain of Bacillus coagulans in an dynamic in vitro model of the stomach and small intestine. Beneficial Microbes 2010, 1: 31-60.
12. Breed, R.S., Murray, E.G.D., Smith, N.R. Bergey's Manual of Determinative Bacteriology, 7th Ed. The Williams and Wilkins Co., Baltimore 1957.
13. Endres, J.R., Clewell, A., Jade, K.A., Farber, T., Hauswirth, J., Schauss, A.G. Safety assessment of a proprietary preparation of a novel probiotic, Bacillus coagulans, as a food ingredient. Food Chem Toxicol 2009, 47(6): 1231-8.
14. International Conference on Harmonisation. Good clinical practice: Consolidated guideline. Fed Regist 1997, 62(90): 25691-709.
15. Sustenex, Ganeden Biotech Inc. www.sustenex.com/professionals/safety aspx. Accessed July 23, 2009.
16. Hun, L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med 2009, 121(2): 119-24.
17. Perdigon, G., Fuller, R., Raya, R. Lactic acid bacteria and their effect on the immune system. Curr Issues Intest Microbiol 2001, 2(1): 27-42.
18. Gaudier, E., Forestier, L., Gouyer, V., Huet, G., Julien, R., Hoebler, C. Butyrate regulation of glycosylation-related gene expression: Evidence for galectin-1 upregulation in human intestinal epithelial goblet cells. Biochem Biophys Res Commun 2004, 325(3): 1044-51.
19. Pham, M., Lemberg, D.A., Day, A.S. Probiotics: Sorting the evidence from the myths. Med J Aust 2008, 188(5): 304-8.
20. Fendrick, A.M., Monto, A.S., Nightengale, B., Sarnes, M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med 2003, 163(4): 487-94.
21. de Vrese, M., Winkler, P., Rautenberg, P. et al. Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial. Vaccine 2006, 24(44-46): 6670-4.
22. Winkler, P., de Vrese, M., Laue, C., Schrezenmeir, J. Effect of a dietary supplement containing probiotic bacteria plus vitamins and minerals on common cold infections and cellular immune parameters. Int J Clin Pharmacol Ther 2005, 43(7): 318-26.
23. Patel, M.A., Ou, M.S., Harbrucker, R., Aldrich, H.C., Buszko, M.L., Ingram, L.O., Shanmugam, K.T. Isolation and characterization of acid-tolerant, thermophilic bacteria for effective fermentation of biomass-derived sugars to lactic acid. Appl Environ Microbiol 2006, 72(5): 3228-35.